Benzinga · Sep 23, 2026
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
CR
NASDAQ · CRDL
Cardiol Therapeutics Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$1.32
Down-$0.01 (-0.76%)
Updated Oct 6, 2026, 9:47 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 94.81M
- P/E ratio
- -3.26
- Dividend yield
- 0.00%
- 52-week range
- $0.90 – $2.34
- Volume
- 2.96M
- Avg. volume
- 704.06K
Price performance · CRDL
CRDL price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CRDL closed at $1.32 after 20 trading sessions, down 40.54% for the selected period.
- Last close
- $1.32
- Period change
- -40.54%
- Period low
- $1.32
- Period high
- $2.29
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.40 | $1.40 | $1.28 | $1.32 | 2.96M |
| Oct 2, 2026 | $1.60 | $1.64 | $1.40 | $1.41 | 3.59M |
| Oct 1, 2026 | $1.61 | $1.648 | $1.52 | $1.56 | 1.83M |
| Sep 30, 2026 | $1.70 | $1.71 | $1.64 | $1.66 | 461.43K |
| Sep 29, 2026 | $1.68 | $1.705 | $1.67 | $1.69 | 678K |
| Sep 28, 2026 | $1.69 | $1.70 | $1.655 | $1.69 | 763.65K |
| Sep 25, 2026 | $1.7499 | $1.75 | $1.67 | $1.71 | 1.01M |
| Sep 24, 2026 | $1.72 | $1.74 | $1.66 | $1.73 | 1.08M |
| Sep 23, 2026 | $1.86 | $1.915 | $1.72 | $1.77 | 2.11M |
| Sep 22, 2026 | $1.86 | $1.955 | $1.855 | $1.89 | 722.28K |
| Sep 21, 2026 | $1.90 | $1.9292 | $1.82 | $1.86 | 1.01M |
| Sep 18, 2026 | $1.88 | $1.98 | $1.835 | $1.875 | 974.69K |
| Sep 17, 2026 | $1.91 | $1.93 | $1.85 | $1.86 | 583.64K |
| Sep 16, 2026 | $1.85 | $1.90 | $1.81 | $1.90 | 1.58M |
| Sep 15, 2026 | $1.96 | $1.9782 | $1.825 | $1.85 | 1.17M |
| Sep 14, 2026 | $1.98 | $2.04 | $1.95 | $1.99 | 1.38M |
| Sep 11, 2026 | $2.03 | $2.0779 | $1.945 | $1.995 | 1.24M |
| Sep 10, 2026 | $2.21 | $2.24 | $1.975 | $1.98 | 1.78M |
| Sep 9, 2026 | $2.22 | $2.34 | $2.21 | $2.285 | 1.97M |
| Sep 8, 2026 | $2.20 | $2.24 | $2.16 | $2.22 | 1.24M |
Latest CRDL news
The latest Smart Investors Daily articles mentioning CRDL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CRDL research
Overview
Company profile and research snapshot.
Company profile
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Aug 13, 2026 | BROOKLINE CAPITAL MARKETS | Buy | — |
| Jul 13, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Jul 12, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| May 12, 2026 | BROOKLINE CAPITAL MARKETS | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce enrollment progress and plans to expand MAVERIC, the Company's pivotal Phase III randomized, double-blind, placebo-controlled, multi-center trial evaluating CardiolRx™ for the reduction in risk of recurrence in patients with recurrent pericarditis. As of September 23, 2026, 110 patie
Benzinga · Sep 23, 2026
Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance."A blinded review of events in MAVERIC patients
Yahoo · Sep 16, 2026
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce it has received proceeds of over USD $7 million from the exercise of outstanding common share purchase warrants. The capital raised will extend Cardiol's cash runway into H1 2028, fund operations through topline data readout from the pivotal Phase III MAVERIC trial of CardiolRx™ in r
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
